Abiomed Inc. stock rose 50% on Tuesday to $377.82 after J&J said it would buy the firm for $380 per share in cash. The stock closed at the highest level since November 2018, after posting its strongest one-day rise since 1989. The deal’s premium is more than 50% higher than the shares closed Monday at $252.08, putting the deal’s premium at $380.08. Prior to the announcement, the stock had lost 30% this year — it’s now up 5.2% for 2022. The price of the deal is $17.3 billion, while J.J. shares slipped 0.5% Tuesday. The premium is “clear JNJ is serious” . . .
Read more at finance.yahoo.com
